Product ID: SQSG35J2001
Global Genome Editing Market Size, Share, Growth Analysis, By Technology(CRISPR, TALEN), By Delivery Method(Ex-vivo, In-vivo), By Mode(Contract, In-house), By End Use(Biotechnology & Pharmaceutical Companies, Academic & Government Research Institutes) - Industry Forecast 2024-2031
Report ID:
SQSG35J2001 |
Region:
Global |
Published Date: February, 2024
Pages:
157
|
Tables:
117 |
Figures:
77
Global Genome Editing Market Insights
Genome Editing Market size was valued at USD 4.81 billion in 2019 and is poised to grow from USD 5.88 billion in 2023 to USD 36.06 billion by 2031, growing at a CAGR of 22.3% in the forecast period (2024-2031).
Genome editing is a technique for making changes to the DNA of a cell or an organism. The process entails cutting DNA sequences to add or remove DNA from the genome. Changes to the genome are made to provide the cell with the traits it needs. Various governments worldwide are expanding their assets and awards to foster genome-altering research. Attributable to genome altering's benefits, governments are also supporting public and private examination and scholastic foundations for expanding the exploration exercises for genome altering and hereditary designing. Hence, this leads to positive Genome Editing Market growth in the given forecast period.
The rising predominance of disease and other hereditary issues, expanding inclination for customized medication, increase in R&D consumption and development of biotechnology and drug businesses, ascend in private and public area financing, quick progressions in sequencing, and Genome Editing advancements are factors impelling the genome editing market.
The increasing use of CRISPR genome editing technology, combined with rising synthetic gene demand in a variety of biotechnology domains, has primarily driven market growth in recent years.
Furthermore, the Genome Editing Market is witnessing increased competition among market players as a result of the expanding applications of genome editing tools. The highly adaptable CRISPR technology has received increased attention. For instance, in April 2021, Vertex Pharmaceuticals paid CRISPR Therapeutics USD 900 million to develop, manufacture, and commercialize CRISPR-Cas9 gene-edited therapy for beta-thalassemia and sickle cell disease. Such initiatives are expected to boost the Genome Editing Market growth.
US Genome Editing Market is poised to grow at a sustainable CAGR for the next forecast year.
Global Genome Editing Market Report Snapshots
Want to customize this report?
Our industry expert will work with you to provide you with customized data in a short amount of time.
REQUEST FREE CUSTOMIZATION
USA (+1) 351-333-4748
